资料参考2015 asco会议会议111974_slide.pptxVIP

Optimizing Adjuvant Therapy with br /Bone-Modifying Agents ;Role of Adjuvant Bisphosphonates In Early Breast Cancer;Outline;Aromatase Inhibitors Result In Increased Bone Loss and Poorer Quality Bone;Aromatase Inhibitors Are Associated With An Increased Rate of Fractures;EBCTCG Bisphosphonate Meta-analysis – Fracture Data;Slide 7;ABCSG 18 – Study Design;ABCSG 18 – Risk of Fractures;Risk of Fractures By Baseline BMD;ABCSG 18 – Bone Mineral Density Changes;Denosumab Decreased New Vertebral Fractures in Prostate Cancer Patients Receiving ADT*;AZURE – Fracture Data;Phase III trial of bisphosphonate